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Abstract
Background: Analyses of Fgf10 and Fgfr2b mutant mice, as well as human studies, suggest that FGF10/FGFR2b
signaling may play an essential, nonredundant role during embryonic SMG development. To address this question,
we have analyzed the SMG phenotype in Fgf10 and Fgfr2b heterozygous and null mutant mice. In addition, although
previous studies suggest that the FGF10/FGFR2b and FGF8/FGFR2c signaling pathways are functionally
interrelated, little is known about the functional relationship between these two pathways during SMG
development. We have designed in vivo and in vitro experiments to address this question.
Results: We analyzed Fgf10 and Fgfr2b heterozygous mutant and null mice and demonstrate dose-dependent
SMG phenotypic differences. Hypoplastic SMGs are seen in Fgf10 and Fgfr2b heterozygotes whereas SMG aplasia
is seen in Fgf10 and Fgfr2b null embryos. Complementary in vitro studies further indicate that FGF10/FGFR2b
signaling regulates SMG epithelial branching and cell proliferation. To delineate the functional relationship
between the FGF10/FGFR2b and FGF8/FGFR2c pathways, we compared the SMG phenotype in Fgfr2c+/∆ /Fgf10+/
- double heterozygous mice to that seen in wildtype, Fgf10+/- (Fgfr2c+/+/Fgf10+/-) and Fgfr2c+/∆  (Fgfr2c+/∆ /Fgf10+/+)
single heterozygous mutant littermates and demonstrate genotype-specific SMG phenotypes. In addition,
exogenous FGF8 was able to rescue the abnormal SMG phenotype associated with abrogated FGFR2b signaling
in vitro and restore branching to normal levels.
Conclusion: Our data indicates that FGF10/FGFR2b signaling is essential for the SMG epithelial branching and
histodifferentiation, but not earliest initial bud formation. The functional presence of other endogenous signaling
pathways could not prevent complete death of embryonic SMG cells in Fgf10 and Fgfr2b null mice. Though we
were able to rescue the abnormal phenotype associated with reduced in vitro FGF10/FGFR2b signaling with
exogenous FGF8 supplementation, our results indicate that the FGF10/FGFR2b and FGF8/FGFR2c are
nonredundant signaling pathways essential for in vivo embryonic SMG development. What remains to be
determined is the in vivo functional relationship between the FGF10/FGFR2b signal transduction pathway and
other key signaling pathways, and how these pathways are integrated during embryonic SMG development to
compose the functional epigenome.
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Background
Mouse submandibular gland (SMG) development is initi-
ated with a thickening of the oral epithelium of the man-
dibular arch around embryonic day 11.5 (E11.5) and is
best conceptualized in stages[1,2]. In the PreBud Stage,
SMG development begins as thickening of the oral epithe-
lium adjacent to the tongue. During the Initial Bud Stage,
this thickening grows down into mandibular arch mesen-
chyme to form the initial SMG bud. With continued epi-
thelial proliferation and downgrowth, the SMG
primordium becomes a solid, elongated epithelial stalk
terminating in a bulb. Repeated end-bud branching
results in the formation of a network of epithelial
branches and terminal buds (the Pseudoglandular Stage).
These epithelial branches and terminal buds hollow out
by cell apoptosis during the Canalicular and Terminal Bud
Stages, respectively, to form the ductal system and pre-
sumptive acini, with mucin protein being produced by the
presumptive acini.
Morphogenesis of complex organs such as the SMG is reg-
ulated by the functional integration of parallel and
broadly related signaling pathways which regulate cell
proliferation, apoptosis and histodifferentiation [3-6]. To
understand the complex interactions within this dynamic
signaling network, one must first determine the contribu-
tion of individual pathways and identify those which play
essential, nonredundant roles during embryonic SMG ini-
tial bud formation, branching morphogenesis and
histodifferentiation.
The FGF family, with at least 22 members, mediates
diverse biological functions such as cell proliferation,
branching morphogenesis and histodifferentiation by
binding and activating four tyrosine kinase receptors
(FGFR 1–4) [see reviews [7-9]]. Tissue-specific alternate
splicing of the Fgfr1, Fgfr2 and Fgfr3 genes generates iso-
forms which differentially bind specific FGF ligands
[8,10]. Ligand-receptor binding potentially activates mul-
tiple intracellular cascades, including the ERK/RAS/
MAPK, P13K, and PLC-γ /PKC pathways [see reviews
[8,9,11]].
Functional studies have demonstrated that embryonic
SMG epithelial cell proliferation, branching morphogene-
sis, and histodifferentation are regulated through growth
factor, cytokine, and transcription factor-mediated signal-
ing pathways, including EGF, TGF-β , Shh, FGFs, and Eda
[2,6,12-21]. Although FGFs have been implicated in
embryonic SMG development [13,15,22-24], a more
complete understanding of their precise roles will provide
insight into the complex network of parallel and broadly-
related signaling pathways which regulate SMG
organogenesis.
Gene targeting studies have clearly shown the importance
of the FGFR2b (FGFR2-IIIb) signaling pathway for embry-
onic morphogenesis [22,23,25]. Fgfr2b-/- null mice die at
birth due to lung insufficiency and exhibit severe dysmor-
phic organs, including agenesis or dysplasia of the lungs,
mammary glands, pancreas, thyroid, teeth, and limbs
[22,23,25,26]. Although FGF1, FGF3, FGF7, and FGF10
bind with high affinity to FGFR2b [8,10], the phenotypic
similarities between Fgf10  and  Fgfr2b  null mice [22-
25,27] indicate that FGF10 is the major ligand for FGFR2b
in vivo. Of particular interest is the absence of SMGs in
E14.5 and older Fgfr2b null mice and newborn Fgf10 null
mice [23-25]. However, whether this glandular absence is
due to the lack of development of a SMG initial bud (i.e.
agenesis) or subsequent aplasia of the initial bud was
heretofore unknown.
Recently, Entesarian et al. [28] have shown the impor-
tance of FGF10 gene dosage for salivary gland develop-
ment in humans. Individuals with autosomal dominant
ALSG (aplasia of lacrimal and salivary gland) exhibit
hypoplastic or absent parotid and submandibular glands.
ALSG was mapped to 5p13.2-5q13.1 to include the FGF10
gene; heterozygous FGF10 mutations were identified in
all family members with ALSG. Complementary study of
adult Fgf10+/- mutant mice revealed that Fgf10 heterozy-
gotes have absent parotid glands and smaller SMGs
although other organs such as lungs, liver, spleen, pan-
creas, thyroid, limbs appeared normal.
Taken together, the literature suggests that FGF10/FGFR2b
signaling plays an essential, nonredundant, dose-depend-
ent role during embryonic SMG development. To address
this postulate, we evaluated SMG development in Fgfr2b
and Fgf10 heterozygous mutant and null mice and dem-
onstrate dose-dependent differences in SMG phenotypes.
In a complementary set of in vitro experiments, we con-
firm the importance of FGF10/FGFR2b signaling and
demonstrate that enhanced FGF10/FGFR2b signaling sig-
nificantly induces, and abrogated FGF10/FGFRb signaling
significantly diminishes, SMG branching morphogenesis
and cell proliferation.
Our previous analyses of mutant mice and functional in
vitro  studies indicate that the FGF8/FGFR2c signaling
pathway is essential for embryonic SMG epithelial
branching morphogenesis and histodifferentiation [2,13].
Little is known about the functional relationship between
the FGF10/FGFR2b and FGF8/FGFR2c pathways during
SMG development. Thus, we evaluated the SMG pheno-
type in Fgfr2c+/∆ /Fgf10+/- double heterozygous mice, com-
pared them to Fgf10+/- (Fgfr2c+/+/Fgf10+/-) and Fgfr2c+/∆
(Fgfr2c+/∆ /Fgf10+/+) single heterozygous mutant, as well as
wildtype (WT), littermates and demonstrate genotype-
specific SMG phenotypes. Though we were able to rescueBMC Developmental Biology 2005, 5:11 http://www.biomedcentral.com/1471-213X/5/11
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the abnormal phenotype associated with reduced in vitro
FGF10/FGFR2b signaling with exogenous FGF8 peptide
supplementation, our results indicate that the FGF10/
FGFR2b and FGF8/FGFR2c are nonredundant signaling
pathways essential for in vivo embryonic SMG
development.
Results
To delineate the role of FGF10/FGFR2b signaling during
embryonic SMG development, we evaluated the SMG
phenotype in Fgf10  and  Fgfr2b  null and heterozygous
mutant mice. The E12.5 normal SMG appears as an elon-
gated solid cord of epithelium terminating in an end-bulb
(i.e., Initial Bud Stage) (Fig. 1A). By contrast, the E12.5
Fgfr2b null SMG is severely hypoplastic (compare Fig. 1B
to 1A), displaying an extremely small initial bud similar to
the earliest Initial Bud Stage [1,2]. A similar phenotype is
seen in Fgf10 null mice (compare Fig. 1C to 1A, B). Nor-
mally by E13.5, epithelial proliferation results in SMG pri-
mordia with end-bulbs characterized by several branches;
SMGs from both Fgfr2b and Fgf10 null mice are entirely
absent (compare Fig. 2B, C to 2A). On the other hand,
Fgfr2b+/-  and  Fgf10+/-  heterozygosity results in SMG
branching hypoplasia compared to WT glands, with fewer
ducts and terminal buds being seen in heterozygous
mutant SMGs than in WT SMG (compare Fig. 3B to 3A, D
to 3C). Taken together, our data indicate that FGF10/
FGFR2b signaling plays an essential, dose-dependent role
during in vivo embryonic SMG branching morphogenesis
and histodifferentation, but not earliest initial bud forma-
tion. Thus, the pathology in null mice is aplasia, not
agenesis.
Enhanced FGF10/FGFR2b signaling in vitro induces 
embryonic SMG branching morphogenesis and epithelial 
cell proliferation
To further delineate the role of FGF10/FGFR2b signaling
during embryonic SMG development, we used our well-
defined organ culture system to analyze the effect of
enhanced FGF10/FGFR2b signaling on embryonic SMG
branching morphogenesis. Paired E13 (Initial Bud Stage)
or E14 (Pseudoglandular Stage) SMG primordia were cul-
tured for up to 3 days in the presence or absence of FGF10
peptide (200 ng/ml or 500 ng/ml). Since a notable differ-
ence in SMG branch number is usually seen among litter-
mates, we compared the number of terminal buds in right
and left glands (treated and control) from each embryo.
Spooner ratios (end bud number/initial bud number)
were determined for each explant, the data were then arc-
sin transformed, and the mean ratios compared by paired
t-test. FGF10 supplementation induced a significant
increase in branching morphogenesis (Fig. 4A, B, E): 81%
for E13 + 3 [200 ng/ml (P < 0.01); 500 ng/ml (P < 0.001)]
and 46% for E14 + 2 [500 ng/ml (P < 0.0001)].
Since cell proliferation is not required for early embryonic
SMG epithelial branching [29], we determined if this
FGF10-induced increase in branching is due to increased
epithelial cell proliferation. We cultured E13+3 SMG pri-
mordia in the presence or absence of 500 ng/ml FGF10
peptide and calculated the epithelial cell proliferation
index (the number PCNA-positive cells/total number of
cells). Exogenous FGF10 induced a significant 78% (P <
0.0001) increase in epithelial cell proliferation compared
to control (Fig. 5). Our results are similar to enhanced
pancreatic epithelial cell proliferation and pancreatic
hyperplasia in transgenic mice with persistent Fgf10
expression in developing pancreatic epithelia [30].
Abrogated FGF10/FGFR2b signaling in vitro decreases 
embryonic SMG branching morphogenesis and cell 
proliferation
We interrupted FGF10/FGFR2b signaling in vitro by add-
ing exogenous soluble FGFR2b-Fc chimera to the culture
Abnormal SMG phenotypes in E12.5 Fgfr2b and Fgf10 null  mutants A Figure 1
Abnormal SMG phenotypes in E12.5 Fgfr2b and Fgf10 
null mutants A. E12.5 WT (+/+) mouse. B. E12.5 Fgfr2b-/- 
(R2b-/-) null mouse. C. E12.5 Fg10-/- null mouse. In the WT 
mouse (A), the Initial Bud Stage SMG is seen in the mandible 
ventrolateral to the tongue. By contrast, the SMG bud (out-
lined in white) in Fgfr2b-/- (B) and Fg10-/- (C) mice is extremely 
small, resembling the earliest Initial Bud Stage SMG. Bar, 50 
µm.BMC Developmental Biology 2005, 5:11 http://www.biomedcentral.com/1471-213X/5/11
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medium to competitively bind endogenous FGFR2b
ligands. This exogenous receptor/ligand binding method-
ology has been successfully used to interrupt FGFR2b,
FGFR2c, FGFR1b and FGFR1c signaling in vitro
[13,15,21]. This experiment was designed to provide an in
vitro model of the in vivo Fgf10+/- heterozygous mutant
SMG phenotype (i.e. SMG hypoplasia). We conducted
dose-response studies and determined the concentration
of FGFR2b-Fc chimera which induces a clear biologic
effect of reduced branching morphogenesis, thereby creat-
ing an in vitro model of the in vivo Fgf10 mutant heterozy-
gote. Paired E13+3 or E14+2 SMG primordia were
cultured in IgG-Fc (5 ng/ml or 10 ng/ml) or FGFR2b-Fc
chimera (5 ng/ml or 10 ng/ml) and Spooner ratios were
determined as described above. E13 + 3 FGFR2b-Fc-
treated explants exhibit a significant 22% [10 ng/ml (P <
0.01)] decrease in branching morphogenesis compared to
controls (Figs. 4C, D, E); a similar 22% reduction [5 ng/
ml (P < 0.001); 10 ng/ml (P < 0.01)] was also seen in
E14+2-treated explants (Figs. 4E). These results mimic the
in vivo heterozygous mutants reported above.
Since exogenous FGF10 supplementation in vitro induced
a significant increase in cell proliferation, we then evalu-
ated the epithelial cell proliferation index in E13 +3 SMG
primordia with or without abrogated FGF10/FGFR2b sig-
naling. A significant 32% (P < 0.001) decrease in cell pro-
liferation was seen in the presence of 10 ng/ml FGFR2b-Fc
chimera compared to control (Fig. 5). Reduction in cell
proliferation with FGFR2b-Fc treatment in vitro was also
reported by Steinberg et al., [21]. These results indicate
that FGF10/FGFR2b signaling modulates embryonic SMG
epithelial cell proliferation and  branching
morphogenesis.
Relationship between FGFR2b and FGFR2c signaling 
pathways during SMG development
Our previous observation of hypoplastic SMGs in Fgfr2c+/
∆  deficient mice suggested that FGFR2c signaling is neces-
sary for embryonic SMG branching morphogenesis and
histodifferentation [2]. The functional importance of this
signaling pathway was confirmed in vitro; reduction of
FGFR2c signaling in vitro resulted in a significant dose-
dependent decrease in branching morphogenesis [13]. In
addition, FGF8, a major FGFR2c ligand, has been shown
to play an essential, nonredundant role during embryonic
SMG development [13]. Like the hypoplastic SMG pheno-
type of Fgfr2c deficient mice, hypoplastic glands are seen
in Fgf8 hypomorphic mice [13]. Importantly, SMG aplasia
is seen in Fgf8 tissue-specific conditional mutant mice. To
investigate the relationship between the FGFR2b and
FGFR2c signal transduction pathways during in vivo SMG
development, we evaluated the SMG phenotype in mice
which are heterozygous for both the Fgf10  and  Fgfr2c
SMG aplasia in Fgfr2b and Fgf10 null mice Figure 2
SMG aplasia in Fgfr2b and Fgf10 null mice. A. E13.5 WT mouse. B. E13.5 Fgfr2b-/- null mouse. C. E13.5 Fg10-/- null mouse. 
The E13.5 WT SMG (A) has achieved the Late Initial Bud Stage, with several branches being seen in the end-bulb epithelium; a 
small sublingual gland (SL) bud is seen lateral to the SMG bud. In Fgfr2b-/- (B) and Fg10-/- (C) embryos, no SMGs are found; undif-
ferentiated mesenchyme is seen in the site normally occupied by SMG epithelia. PS-palatal shelf. Bar, 50 µm.BMC Developmental Biology 2005, 5:11 http://www.biomedcentral.com/1471-213X/5/11
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genes (i.e. Fgfr2c+/∆ /Fgf10+/- mutants). Mutant mice heter-
ozygous for either Fgfr2c  (Fgfr2c+/∆ /Fgf10+/+) or Fgf10
(Fgfr2c+/+/Fgf10+/-) exhibit hypoplastic SMGs compared to
WT (Fgfr2c+/+/Fgf10+/+) littermates (compare Fig. 6B, C to
6A). In contrast, Fgfr2c+/∆ /Fgf10+/- double heterozygous
mutant SMGs are smaller and exhibit fewer ducts and ter-
minal buds than seen in single heterozygous Fgfr2c+/∆ /
Fgf10+/+ or Fgfr2c+/+/Fgf10+/- mutant glands (compare Fig.
6D to 4B, C). These results suggest that, during embryonic
SMG development, the FGFR2b and FGFR2c signal trans-
duction pathways each induce at least some downstream
targets that are idiosyncratic and not coincident.
FGF8 rescues SMGs with interrupted FGF10/FGFR2b in 
vitro
Given that FGF8-mediated signaling plays an essential
and unique role during SMG development [13], as well as
our observation in Fgfr2c+/∆ /Fgf10+/- double heterozygous
mutant mice discussed above, we postulated that exoge-
nous FGF8 peptide would rescue the abnormal SMG phe-
notype associated with abrogated FGFR2b signaling in
vitro. To determine if exogenous FGF8 peptide supple-
mentation could restore branching morphogenesis to
normal, we interrupted SMG morphogenesis in vitro with
FGFR2b-Fc chimera and attempted to "rescue" these
explants and restore branching to the level seen in
controls. We cultured paired E13 + 3 SMGs in 10 ng/ml
FGFR2b-Fc chimera for an initial period of 3 hours and
then in FGFR2b-Fc + 500 ng/ml FGF8 peptide or FGFR2b-
Fc alone for a total of 3 days (Fig. 7A, B). A second exper-
iment to confirm that exogenous FGFR2b-Fc chimera
decreased SMG branching morphogenesis consisted of
paired E13 + 3 cultured in the presence of 10 ng/ml
FGFR2b-Fc or IgG-Fc. In this set of experiments, FGFR2b-
Hypoplastic SMGs are seen in Fgfr2b and Fgf10 heterozygous mice Figure 3
Hypoplastic SMGs are seen in Fgfr2b and Fgf10 heterozygous mice. A. Newborn WT Fgfr2b+/+ SMG. B. Newborn 
Fgfr2b+/- heterozygous SMG. C. Newborn WT Fgf10+/+ SMG. D. Newborn Fg10+/- heterozygous SMG. WT Fgfr2b+/+ (A) and 
Fgf10+/+ (C) mice exhibit Late Terminal Bud Stage SMGs consisting of ducts and terminal buds displaying distinct lumina. In con-
trast, fewer ducts and terminal buds are seen in Fgfr2b+/- (B) and Fg10+/- (D) heterozygous SMGs compared to WT littermates. 
Bar, 50 µm.BMC Developmental Biology 2005, 5:11 http://www.biomedcentral.com/1471-213X/5/11
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Fc-treated explants exhibit a significant 20% (P < 0.001)
decrease in branching compared to IgG-Fc controls (Fig.
7C). Addition of exogenous FGF8 peptide induced a sig-
nificant 24% (P < 0.02) increase in branching compared
to FGFR2b-Fc treatment alone, thus completely restoring
branching morphogenesis to the level seen in controls
(Fig. 7C).
Discussion
The FGF family of growth factors is critical to normal
embryogenesis, regulating cell proliferation, survival and
apoptosis [8]. Analyses of Fgfr2b and Fgf10 mutant and
null mice clearly demonstrate that the FGF10/FGFR2b sig-
nal transduction pathway is essential for the development
of branching organs, including the lung, mammary gland,
lacrimal gland, pancreas, thyroid gland and salivary gland
[23-28,31-33]. Although SMGs were absent from E14.5 or
older Fgfr2b null mice and newborn Fgf10 null mice [22-
25], the presence of an initial SMG bud in E12.5 Fgf10 and
Fgfr2b null embryos (Fig. 1) indicates that this is a true
aplasia, and not agenesis. Moreover, the absence of SMGs
in E13.5 and older Fgfr2b-/- and Fgf10-/- mutants confirms
that FGF10/FGFR2b signaling is essential for earliest ini-
tial epithelial branching and subsequent Pseudoglandular
Stage and older SMG morphogenesis, but not earliest ini-
tial bud formation.
The observed initial SMG bud formation and subsequent
aplasia is consistent with the pathogenesis seen in other
organs, including the Fgfr2b null mammary gland [26],
but differs from that seen in lung and pancreas [24,31,34].
Interestingly, Bellusci and colleagues [26] also detected
genotype-specific phenotypic differences in mammary
bud formation. A transient single initial mammary gland
bud (bud 4) seen in E11.5 Fgfr2b-/- mice is absent in E12.5
mice whereas bud 4 is maintained (but does not branch)
in Fgf10-/- mice. This result suggests that FGFR2b signaling
is essential to maintain bud 4 and to induce the other
Enhanced or abrogated FGF10/FGFR2b signaling modulates embryonic SMG branching morphogenesis in vitro Figure 4
Enhanced or abrogated FGF10/FGFR2b signaling modulates embryonic SMG branching morphogenesis in 
vitro. A-B. Enhanced signaling. Paired E13 SMG primordia were cultured for 3 days in the absence (A) or presence (B) of 500 
ng/ml FGF10 peptide supplementation. FGF10 induced a significant increase in branching compared to control (CONT). C-D. 
Abrogated signaling. Paired E13 SMG primordia were cultured for 3 days in 10 ng/ml IgG-Fc (C) or FGFR2b-Fc chimera (D). 
FGFR2b-Fc chimera treated explant exhibits a significant decrease in branching compared to IgG-Fc control. Bar, 30 µm. E. 
Comparison of mean Spooner ratios in E13 + 3 and E14 + 2 explants. Exogenous FGF10 peptide supplementation induced a 
significant 81% increase in E13 +3 explants [200 ng/ml (P < 0.01); 500 ng/ml (P < 0.001)] and a significant 46% increase in E 14 
+ 2 explants (P < 0.0001) compared to controls. FGFR2b-Fc chimera-mediated interruption of E13 + 3 and E 14 + 2 SMGs sig-
nificantly reduced branching morphogenesis by 22% [E13 +3: 10 ng/ml (P < 0.01); E 14 + 2: 5 ng/ml (P > 0.0001); 10 ng/ml (P < 
0.01)] compared to controls.BMC Developmental Biology 2005, 5:11 http://www.biomedcentral.com/1471-213X/5/11
Page 7 of 12
(page number not for citation purposes)
mammary placodes whereas another FGFR2b ligand
(probably FGF7) acts redundantly with FGF10 to
maintain the mammary gland placode. Similarly, differ-
ences in pancreatic development were observed between
Fgf10 and Fgfr2b null mice [31,35]. Taken together, these
results clearly indicate that Fgfr2b and Fgf10 null mice
demonstrate tissue-specific differences in affected organs.
Although  Fgf10+/- heterozygous mice were described as
being normal [24,34], lacrimal, parotid and submandibu-
lar gland aplasia or hypoplasia were recently reported in
adult Fgf10+/- mice and in ALSG patients with FGF10 het-
erozygous mutations [28]. To determine if Fgfr2b  and
Fgf10 gene dosage plays an important role during embry-
onic SMG development, we evaluated newborn Fgfr2b+/-
and Fgf10+/- and found SMG hypoplasia in both (Fig. 3).
This is the first report of organ abnormality in Fgfr2b het-
erozygous mice. Our data indicate that SMG development
is Fgf10 and Fgfr2b  dose-dependent. Homozygous null
mutants exhibit SMG aplasia while heterozygotes exhibit
SMG hypoplasia. Moreover, the observations of normal
lungs, livers, and limbs [23-25,28,34], but abnormal SMG
phenotypes [28], in Fgfr2b+/- and  Fgf10+/- mutant mice
provides additional evidence of FGF10/FGFR2b tissue-
specificity.
Relationship between FGF10/FGFR2b and FGF8/FGFR2c 
signaling pathways
It is critical to remember that FGF10 binding to FGFR2b is
part of a much larger genetic network. Organogenesis is
the programmed expression of regulatory genes coupled
to downstream structural genes and epigenetic events.
Specific signaling pathways are parallel and largely func-
tionally redundant; that is, several pathways differentially
and combinatorially compensate for the dysfunction of a
given individual pathway. There are some pathways, how-
ever, that have unique and nonredundant functions. One
has always to ask two key questions: Is our pathway of
interest functionally redundant or nonredundant? Will a
broadly related, not independent, pathway compensate
for the dysfunction of our pathway of interest?
The observation of SMG aplasia in Fgf10 and Fgfr2b null
mice indicates that the functional presence of other
endogenous FGF/FGFR pathways (e.g., FGF8/FGFR2c,
FGF/FGFR1) or other signaling pathways (e.g., TGF-α /
EGF/EGFR, Eda/Edar; IGF-II/IGF-IR) could not prevent
complete death of embryonic SMG cells in Fgf10-/- and
Fgfr2b-/- mice. Interestingly, although SMG aplasia was
also seen in Fgf8  (Fgf8C/N;AP2α IRESCre/+) conditional
mutant mice in which Fgf8 expression was ablated from
first branchial arch epithelium, a small initial SMG bud is
still seen in E15.5 embryos [13]. By contrast, the Fgf10and
Fgfr2b null SMG bud is much more transient, being seen
in E12.5 and absent in E13.5 mice (present study). This
suggests that the FGF10/FGFR2b and FGF8/FGFR2c sign-
aling pathways are both essential for branching and that
the FGF10/FGFR2b signal is necessary for epithelial bud
maintenance at earlier stages than the FGF8/FGFR2c
signal.
The absence of SMGs in both Fgf8C/N; AP2α IRESCre/+ condi-
tional mutant [13] and Fgf10-/- null mice (present study)
suggests that FGF8 and FGF10 probably induce some of
the same downstream targets, although through different
receptors (FGF10/FGFR2b and FGF8/FGFR2c). However,
the mere fact of ontogenic arrest and SMG aplasia, as well
as temporal differences, in Fgf8 conditional mutants and
Fgf10 and Fgfr2b null mice indicate that FGF10/FGFR2b
and FGF8/FGFR2c signaling pathways induce broadly-
Enhanced or abrogated FGF10/FGFR2b signaling modulates  cell proliferation Figure 5
Enhanced or abrogated FGF10/FGFR2b signaling 
modulates cell proliferation. The cell proliferation index 
of E13 + 3 explants was calculated as the number of PCNA 
positive epithelial cells/total epithelial cells. Exogenous FGF10 
peptide induced a significant 78% (P < 0.0001) increase, and 
FGFR2b-Fc chimera resulted in a significant 32% (P < 0.001) 
decrease, in cell proliferation compared to control.BMC Developmental Biology 2005, 5:11 http://www.biomedcentral.com/1471-213X/5/11
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Fgfr2c+/∆ /Fgf10+/- double heterozygous mutant SMG is severely hypoplastic Figure 6
Fgfr2c+/∆ /Fgf10+/- double heterozygous mutant SMG is severely hypoplastic. A. Newborn R2c+/+/Fgf10+/+ WT SMG. B. 
Newborn R2c+/∆ /Fgf10+/+ (Fgfr2c+/∆ /Fgf10+/+) single heterozygous mutant SMG. C. Newborn R2c+/+/Fgf10+/-(Fgfr2c+/+/Fgf10+/-) 
single heterozygous mutant SMG. D. Newborn R2c+/∆ /Fgf10+/-(Fgfr2c+/∆ /Fgf10+/-) double heterozygous mutant SMG. The 
Fgfr2c+/∆ /Fgf10+/+ (B) and Fgfr2c+/+/ Fgf10+/- (C) single heterozygous SMGs have fewer ducts and terminal buds than seen in WT 
littermates (A). A much smaller, severely hypoplastic gland is seen in Fgfr2c+/∆ /Fgf10+/- double heterozygous mice (D) compared 
to Fgfr2c+/∆ /Fgf10+/+ (B) and Fgfr2c+/+/Fgf10+/- (C) littermates. Bar, 50 µm.BMC Developmental Biology 2005, 5:11 http://www.biomedcentral.com/1471-213X/5/11
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related, but unique and nonredundant downstream
cascades in SMGs that cannot be compensated by normal
function of the other under physiologic conditions. Our
observation of smaller and more severely hypoplastic
SMGs in Fgfr2c+/∆ /Fgf10+/- double heterozygous mice com-
pared to either the Fgfr2c+/∆  or Fgf10+/- single heterozygous
mutants further supports this conclusion.
It is well established that FGF/FGFR signaling can simul-
taneously activate multiple signaling cascades (e.g., ERK/
RAS/MAPK, P13K, and PLC-γ /PKC to mediate epithelial
cell proliferation, survival and histodifferentiation
[8,9,11]. Inhibition of ERK/RAS/MAPK or P13K signaling
significantly reduced embryonic SMG branching morpho-
genesis  in vitro [17-19,21], whereas inhibition of PKC
modestly increased morphogenesis [18]. A recent study of
FGFR2b signaling in vitro suggests that FGF10/FGFR2b
requires ERK activation to mediate cell proliferation and
branching whereas FGF7/FGFR2b requires both ERK and
P13K activation [21].
Although the importance of ERK/RAS/MAPK, P13K and
PKC signaling during embryonic SMG development in
vitro has been demonstrated, it is presently unclear which
signaling cascades downstream of the FGF10/FGFR2b and
FGF8/FGFR2c pathways are essential for epithelial
branching morphogenesis, proliferation and survival dur-
ing in vivo SMG development. This is important because in
vitro and in vivo results may not necessarily coincide, sug-
gesting the effect of differing physiologic conditions.
Recently, Steinberg et al. [21] demonstrated that, in vitro,
once the gland is formed, inhibition of FGF10 does not
inhibit branching. This is the precise opposite of that seen
in both the Fgf10-/- null mice and the Fgf10+/- heterozy-
gotes in vivo (Fig. 1C, 2C, 3C), as well as FGF10 hetero-
zygous mutant individuals with ALSG syndrome [28].
Fgf10 (Fgf10-/-) or Fgfr2b (Fgfr2b-/-) loss of function is ulti-
mately epistatic to each other and to the epigenome under
normal physiologic conditions (i.e. no other gene muta-
tions nor untoward environments), the very reason they
are critical to SMG morphogenesis. However, since the
epistasis associated with declining Fgf10 or Fgfr2b func-
tion is a nonlinear emergent property of the complete
functional epigenotype, it can be manipulated in vitro in
the manner reported here. Exogenous FGF8 peptide can
completely rescue and restore to normal the abnormal
phenotype seen with abrogated FGF10/FGFR2 signaling
Exogenous FGF8 supplementation in vitro rescues SMG branching morphogenesis Figure 7
Exogenous FGF8 supplementation in vitro rescues SMG branching morphogenesis. Paired E13 embryonic SMGs 
were preincubated for 3 hrs in 10 ng/ml FGFR2b-Fc chimera and then cultured for a total of 3 days with/without 500 ng/ml 
FGF8 peptide. A. E13+3 10 ng/ml FGFR2b-Fc-treated explant. B. E13+3 FGFR2b-Fc chimera + FGF8-treated explant. Bar, 30 
µm. C. Comparison of Spooner ratios. A significant 20% (P < 0.001) decrease in branching morphogenesis with FGFR2b-Fc chi-
mera abrogation was seen compared to IgG-Fc control. Exogenous FGF8 supplementation induced a significant 24% (P < 0.02) 
increase in branching to completely restore branching to the level seen in control.BMC Developmental Biology 2005, 5:11 http://www.biomedcentral.com/1471-213X/5/11
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in vitro (Fig. 7). This is not surprising since FGF8 has the
ability to simultaneously activate similar, as well as
unique and ligand-specific, intracellular cascades which
control proliferation, survival, and differentiation. Rescue
experiments have always to be only a proof of this princi-
ple, not a mimic of the in vivo condition. After all, Fgf10-/-
and Fgfr2b-/- mutant SMGs are not rescued in vivo, the very
essence of epistatic mutations. What remains to be deter-
mined is the in vivo functional relationship between the
FGF10/FGFR2b signal transduction pathway and other
key downstream signaling pathways, and how these path-
ways are integrated during embryonic SMG development
to compose the functional epigenome.
Conclusion
Our results indicate that FGF10/FGFR2b signaling is
essential for the SMG epithelial branching and histodiffer-
entiation, but not earliest initial bud formation. The func-
tional presence of other endogenous FGF pathways or
other signaling pathways could not prevent complete
death of embryonic SMG cells in Fgf10 and Fgfr2b null
mice. Moreover, our analysis of Fgfr2c+/∆ /Fgf10+/- double
heterozygous mice indicates that FGF10/FGFR2b and
FGF8/FGFR2c signaling pathways induce broadly-related,
but unique and nonredundant downstream cascades in
SMGs. What remains to be determined is the in vivo func-
tional relationship between the FGF10/FGFR2b signal
transduction pathway and other key downstream signal-
ing pathways, and how these pathways are integrated dur-
ing embryonic SMG development to compose the
functional epigenome.
Methods
Fgf10 and Fgfr2b mutant mice
Fgf10 and Fgfr2b mutant mice were generated on a C57Bl/
6 background and genotyped by RT-PCR as previously
described [23,26,34]. Wildtype mice (WT) (littermates or
otherwise) were used as controls. WT (E11.5-E18.5),
Fgf10-/-  (E11.5-5-E14.5) and Fgfr2b-/-  (E11.5-E15.5)
embryos were collected. For analysis of heterozygous
SMGs, WT and heterozygous mice were mated and new-
born Fgf10+/-, Fgfr2b+/- and WT littermates were collected
and their genotypes confirmed by RT-PCR. The embryos
and newborn heads were fixed in 4% paraformaldehyde
in PBS, and stored in 70% ethanol until further process-
ing. E11.5-E14.5 heads and E15 and older SMGs were
processed, embedded in paraplast and serial coronal sec-
tions were stained with hematoxylin and eosin as
previously described [1]. A minimum of 3 SMGs per age
per genotype were analyzed.
Generation of Fgfr2c+/∆ /Fgf10 +/- mice
Due to their neonatal lethality, Fgfr2-IIIc+/∆  mice are rou-
tinely generated by crossing males in which a copy of
FgfR2-exon 9 (IIIc) has been flanked by loxP sites [36],
with females carrying a PGK-Cre transgene [37]. However,
to obtain the Fgfr2-IIIc +/∆ ;Fgf-10 +/- allele, we used PGK-
Cre females in to which we had previously introduced a
heterozygous Fgf10 null allele (Fgf10 +/-) [27]. For simplic-
ity, the Fgfr2-IIIc +/∆ ;Fgf-10 +/- is called Fgfr2c +/∆ /Fgf-10 +/-.
This cross resulted in the recovery of the following geno-
types in the correct Mendelian ratios: Fgfr2c +/+/ Fgf10 +/+
(WT); Fgfr2c +/+/ Fgf10 +/-, Fgfr2c +/∆ /Fgf-10 +/+ and Fgfr2c +/
∆ /Fgf-10 +/- [36]. Lines were maintained and crosses were
performed in a C57/black 6 background. E17-newborn
WT and mutant mice were generated, SMGs were fixed
and processed as described above, and their genotypes
confirmed by RT-PCR as previously described [27,36]. All
animal studies were conducted with the approval of the
appropriate committees regulating animal research.
Culture system
Timed-pregnant females [C57Bl/10 (B10.A)] were sacri-
ficed on day 13 and day 14 of gestation, and embryos
were dissected in cold PBS and staged according to Theiler
[38]. E13 (Initial Bud Stage) and E14 (Pseudoglandular
Stage) SMG primordia were cultured for up to 3 days
using a modified Trowell method as previously described
[6]. The medium consisted of BGJb (Life Technologies,
Rockville, MD) supplemented with 1% BSA, 0.5 mg
ascorbic acid/ml and 50 units penicillin/streptomycin
(Life Technologies), pH 7.2, and replicate cultures were
changed every day. Supplementation studies: paired E13 and
E14 SMG primordia were cultured in the absence or pres-
ence of exogenous FGF10 peptide (200 or 500 ng/ml, R
and D Systems) for 3 days (E13 + 3) or 2 days (E14 + 2),
respectively; controls consisted of enriched BGJb alone.
Because a notable difference in SMG epithelial branch
number is seen between embryos within a given litter and
among litters, we calculated the Spooner branch ratios
(end bud number/initial bud number) for each explant as
previously described [13] and compared the Spooner
branch ratios in right and left glands (treated and control)
from each embryo. Mean Spooner ratios were deter-
mined, the data were arcsin transformed to insure nor-
mality and homoscedasticity, and compared by paired t-
test for all embryos studied [39]. In this set of experi-
ments, 4–6 explants per treatment were analyzed.
Interruption studies
We interrupted FGF10/FGFR2b signaling using soluble
FGFR2b-Fc chimera (R & D Systems, Inc). This method
has been successfully used to interrupt FGFR2b, FGFR2c,
FGFR1b and FGFR1c signaling during embryonic SMG
development [13,15,21]. We conducted dose-response
studies in which we cultured paired E13 + 3 or E14 + 2
SMG primordia in the presence of soluble FGFR2b-Fc chi-
mera (5 or10 ng/ml) or control IgG-Fc (5 or 10 ng/ml IgG-
Fc; R & D Systems, Inc), analyzed Spooner ratios as
described above, and determined the optimal FGFR2b-FcBMC Developmental Biology 2005, 5:11 http://www.biomedcentral.com/1471-213X/5/11
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chimera concentration which results in a hypoplastic
gland similar to that seen in the in vivo Fgf10 mutant het-
erozygotes. In this set of experiments, 4–8 explants per
treatment were analyzed. Based on this set of experiments,
we used 10 ng/ml FGFR2b-Fc chimera in all subsequent
interruption experiments.
Cell proliferation assay
The cell proliferation index was determined as previously
described [6]. Paired E13 + 3 were cultured in 10 ng/ml
FGFR2b-Fc or 10 ng/ml IgG-Fc, fixed in 10% formalin,
embedded in paraffin and serially-sectioned. The sections
were stained with anti-PCNA for 1 hr using the Zymed
mouse PCNA kit (South San Francisco, CA) and counter-
stained with hematoxylin as previously described [13].
The development time was adjusted according to experi-
ment: 2–5 min for supplementation studies and 10–15
min for interruption studies. In these experiments, the
cytoplasm appears blue and PCNA-positive cells appear
brown. Three explants per group were analyzed. Control
and treated explants were serially-sectioned and the mid-
point of each explant identified. The section showing the
explant's mid-point was selected, as well as the fourth sec-
tion to the right and the fourth section to the left of the
midpoint. This design insured that different buds were
counted in each of the 3 sections/treatment. In each sec-
tion, we photographed terminal bud clusters in the upper
left and lower right at 400 × and counted a minimum of 3
buds/area.
Cell proliferation was quantitated as the ratio of PCNA-
positive epithelial cells/total epithelial cells. The mean cell
proliferation index was determined per section and the
mean cell proliferation index of the three sections/explant
was determined for each treatment. The data was arcsin
transformed and the means ratios compared by t-test.
Rescue experiment
Paired E13 SMG primordia were cultured in 10 ng/ml
FGFR2b-Fc chimera for an initial period of 3 hrs and then
each pair was cultured in FGFR2b-Fc or FGFR2b-Fc + 500
ng/ml FGF8 (R and D Systems, Inc.) for 3 days. This FGF8
peptide concentration was determined to induce a signif-
icant increase in branching morphogenesis (data not
shown). A concurrent control experiment was conducted
as an internal control to verify that FGFR2b-Fc chimera
supplementation interrupted branching morphogenesis;
these controls consisted of E13 primordia cultured in 10
ng/ml FGFR2b-Fc chimera or 10 ng/ml IgG-Fc for 3 days.
The explants were collected and mean Spooner ratios
determined and compared as described above. Four
explants per treatment were analyzed.
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